• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

FDA Approved Treatments: Topical Ruxolitinib and Vitiligo Management

Author(s):

Andrea Rosik, PA-C

Related Videos
4 experts are featured in this series.
2 experts in this video
2 experts in this video
4 experts are featured in this series.
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Dupilumab and AD: Pediatric Ocular Adverse Effects
March 20th 2025

Dupilumab and AD: Pediatric Ocular Adverse Effects

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Patients and Providers Seek More Effective, Time-Saving Treatments for Seborrheic Dermatitis
March 19th 2025

Patients and Providers Seek More Effective, Time-Saving Treatments for Seborrheic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis
March 13th 2025

New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD
March 12th 2025

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD

© 2025 MJH Life Sciences

All rights reserved.